Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2619
Title: Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases
Authors: Heath, C. H.
Ong, C. W.
Chen, S. C. A.
Clark, J. E. 
Halliday, C. L.
Kidd, S. E.
Marriott, D. J.
Marshall, C. L.
Morris, A. J.
Morrissey, C. O.
Roy, R.
Slavin, M. A.
Stewardson, A. J.
Worth, L. J.
Issue Date: 2019
Source: 49, (10), 2019, p. 1229-1243
Pages: 1229-1243
Journal: Internal Medicine Journal
Abstract: Candida auris is an emerging drug-resistant yeast responsible for hospital outbreaks. This statement reviews the evidence regarding diagnosis, treatment and prevention of this organism and provides consensus recommendations for clinicians and microbiologists in Australia and New Zealand. C. auris has been isolated in over 30 countries (including Australia). Bloodstream infections are the most frequently reported infections. Infections have crude mortality of 30–60%. Acquisition is generally healthcare-associated and risks include underlying chronic disease, immunocompromise and presence of indwelling medical devices. C. auris may be misidentified by conventional phenotypic methods. Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry or sequencing of the internal transcribed spacer regions and/or the D1/D2 regions of the 28S ribosomal DNA are therefore required for definitive laboratory identification. Antifungal drug resistance, particularly to fluconazole, is common, with variable resistance to amphotericin B and echinocandins. Echinocandins are currently recommended as first-line therapy for infection in adults and children ≥2 months of age. For neonates and infants <2 months of age, amphotericin B deoxycholate is recommended. Healthcare facilities with C. auris should implement a multimodal control response. Colonised or infected patients should be isolated in single rooms with Standard and Contact Precautions. Close contacts, patients transferred from facilities with endemic C. auris or admitted following stay in overseas healthcare institutions should be pre-emptively isolated and screened for colonisation. Composite swabs of the axilla and groin should be collected. Routine screening of healthcare workers and the environment is not recommended. Detergents and sporicidal disinfectants should be used for environmental decontamination.L20032269962019-10-22
2019-10-31
DOI: 10.1111/imj.14612
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L2003226996&from=exporthttp://dx.doi.org/10.1111/imj.14612 |
Keywords: clinical feature;diagnostic accuracy;disinfection;drug efficacy;drug potentiation;drug response;fungal detection;fungus culture;fungus growth;fungus isolation;fungus transmission;genotype;hand washing;human;laboratory diagnosis;loading drug dose;matrix assisted laser desorption ionization time of flight mass spectrometry;minimum inhibitory concentration;mortality;mycosis;New Zealand;nonhuman;priority journal;sensitivity and specificity;prevalence;itraconazole;micafungin;posaconazole;pyrrole;RNA 28S;sodium chloride;voriconazole;amplified fragment length polymorphism;antifungal resistance;amphotericin Bamphotericin B deoxycholate;anidulafungin;caspofungin;chloramphenicol;echinocandin;fluconazole;flucytosine;gentamicin;internal transcribed spacer;isavuconazole;antifungal susceptibility;article;Australia;bloodstream infection;Candida auris;Candida auris infection;candidemia
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

68
checked on Mar 18, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.